# Sacituzumab Govitecan In TNBC

Source: https://onco.cc/trials/nct04230109/  
OnCo record `nct04230109` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Massachusetts General Hospital, now recruiting.

## Summary

Sacituzumab Govitecan In TNBC is a phase 2, interventional study registered as NCT04230109 by Massachusetts General Hospital, with a registry enrolment figure of 239 participants, started 2020-07-14 and due to reach its primary completion in 2028-10. Interventions recorded: Sacituzumab Govitecan; Pembrolizumab. Conditions listed: Invasive Breast Cancer; Triple Negative Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; HER2-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: NeoSTAR
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04230109
- Phase: 2
- Setting: A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
- Sponsor: Massachusetts General Hospital
- Enrolled: 239

## Sources

- ClinicalTrials.gov NCT04230109: https://clinicaltrials.gov/study/NCT04230109

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04230109.json